Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C

Jennifer Loftis, Robert E. Socherman, Charles D. Howell, Ashlee J. Whitehead, Jo Ann Hill, Jason A. Dominitz, Peter Hauser

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Thirty-nine patients with hepatitis C viral infection on interferon-α (IFN-α) therapy were monitored weekly using the Beck Depression Inventory (BDI). Thirteen of thirty-nine patients (33%) developed IFN-α-induced major depressive disorder (MDD). During the course of IFN-α therapy, patients who became depressed were treated with citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Results indicated that: (1) IFN-α response rates were significantly higher in those patients who developed IFN-α-induced MDD than in those who did not (end-of-treatment response (ETR) rates: 61.5% versus 26.9% and sustained viral response (SVR) rates: 38.5% versus 11.5%), (2) male patients with ETR to IFN-α therapy were, on average, ∼33 pounds lighter in body weight than male patients who did not respond, and (3) gender, race, past history of MDD, and past history of substance abuse were not significantly associated with ETR. In conclusion, our findings suggest that IFN-α-induced MDD may be a predictor of a positive response to IFN-α therapy, or an indication of optimal dosing.

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalNeuroscience Letters
Volume365
Issue number2
DOIs
StatePublished - Jul 22 2004

Fingerprint

Hepatitis C
Interferons
Depression
Major Depressive Disorder
Therapeutics
Citalopram
Serotonin Uptake Inhibitors
Virus Diseases
Antidepressive Agents
Substance-Related Disorders
Body Weight
Equipment and Supplies

Keywords

  • Antidepressants
  • Antiviral therapy
  • Depression
  • Hepatitis C
  • Selective serotonin reuptake inhibitors

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Loftis, J., Socherman, R. E., Howell, C. D., Whitehead, A. J., Hill, J. A., Dominitz, J. A., & Hauser, P. (2004). Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C. Neuroscience Letters, 365(2), 87-91. https://doi.org/10.1016/j.neulet.2004.04.058

Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C. / Loftis, Jennifer; Socherman, Robert E.; Howell, Charles D.; Whitehead, Ashlee J.; Hill, Jo Ann; Dominitz, Jason A.; Hauser, Peter.

In: Neuroscience Letters, Vol. 365, No. 2, 22.07.2004, p. 87-91.

Research output: Contribution to journalArticle

Loftis, Jennifer ; Socherman, Robert E. ; Howell, Charles D. ; Whitehead, Ashlee J. ; Hill, Jo Ann ; Dominitz, Jason A. ; Hauser, Peter. / Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C. In: Neuroscience Letters. 2004 ; Vol. 365, No. 2. pp. 87-91.
@article{94f514e0d54e48e19779665eff4f14b9,
title = "Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C",
abstract = "Thirty-nine patients with hepatitis C viral infection on interferon-α (IFN-α) therapy were monitored weekly using the Beck Depression Inventory (BDI). Thirteen of thirty-nine patients (33{\%}) developed IFN-α-induced major depressive disorder (MDD). During the course of IFN-α therapy, patients who became depressed were treated with citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Results indicated that: (1) IFN-α response rates were significantly higher in those patients who developed IFN-α-induced MDD than in those who did not (end-of-treatment response (ETR) rates: 61.5{\%} versus 26.9{\%} and sustained viral response (SVR) rates: 38.5{\%} versus 11.5{\%}), (2) male patients with ETR to IFN-α therapy were, on average, ∼33 pounds lighter in body weight than male patients who did not respond, and (3) gender, race, past history of MDD, and past history of substance abuse were not significantly associated with ETR. In conclusion, our findings suggest that IFN-α-induced MDD may be a predictor of a positive response to IFN-α therapy, or an indication of optimal dosing.",
keywords = "Antidepressants, Antiviral therapy, Depression, Hepatitis C, Selective serotonin reuptake inhibitors",
author = "Jennifer Loftis and Socherman, {Robert E.} and Howell, {Charles D.} and Whitehead, {Ashlee J.} and Hill, {Jo Ann} and Dominitz, {Jason A.} and Peter Hauser",
year = "2004",
month = "7",
day = "22",
doi = "10.1016/j.neulet.2004.04.058",
language = "English (US)",
volume = "365",
pages = "87--91",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Association of interferon-α-induced depression and improved treatment response in patients with hepatitis C

AU - Loftis, Jennifer

AU - Socherman, Robert E.

AU - Howell, Charles D.

AU - Whitehead, Ashlee J.

AU - Hill, Jo Ann

AU - Dominitz, Jason A.

AU - Hauser, Peter

PY - 2004/7/22

Y1 - 2004/7/22

N2 - Thirty-nine patients with hepatitis C viral infection on interferon-α (IFN-α) therapy were monitored weekly using the Beck Depression Inventory (BDI). Thirteen of thirty-nine patients (33%) developed IFN-α-induced major depressive disorder (MDD). During the course of IFN-α therapy, patients who became depressed were treated with citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Results indicated that: (1) IFN-α response rates were significantly higher in those patients who developed IFN-α-induced MDD than in those who did not (end-of-treatment response (ETR) rates: 61.5% versus 26.9% and sustained viral response (SVR) rates: 38.5% versus 11.5%), (2) male patients with ETR to IFN-α therapy were, on average, ∼33 pounds lighter in body weight than male patients who did not respond, and (3) gender, race, past history of MDD, and past history of substance abuse were not significantly associated with ETR. In conclusion, our findings suggest that IFN-α-induced MDD may be a predictor of a positive response to IFN-α therapy, or an indication of optimal dosing.

AB - Thirty-nine patients with hepatitis C viral infection on interferon-α (IFN-α) therapy were monitored weekly using the Beck Depression Inventory (BDI). Thirteen of thirty-nine patients (33%) developed IFN-α-induced major depressive disorder (MDD). During the course of IFN-α therapy, patients who became depressed were treated with citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Results indicated that: (1) IFN-α response rates were significantly higher in those patients who developed IFN-α-induced MDD than in those who did not (end-of-treatment response (ETR) rates: 61.5% versus 26.9% and sustained viral response (SVR) rates: 38.5% versus 11.5%), (2) male patients with ETR to IFN-α therapy were, on average, ∼33 pounds lighter in body weight than male patients who did not respond, and (3) gender, race, past history of MDD, and past history of substance abuse were not significantly associated with ETR. In conclusion, our findings suggest that IFN-α-induced MDD may be a predictor of a positive response to IFN-α therapy, or an indication of optimal dosing.

KW - Antidepressants

KW - Antiviral therapy

KW - Depression

KW - Hepatitis C

KW - Selective serotonin reuptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=3042733296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042733296&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2004.04.058

DO - 10.1016/j.neulet.2004.04.058

M3 - Article

VL - 365

SP - 87

EP - 91

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -